Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXYM1H)

Drug Name
Visilizumab Drug Info
Synonyms Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMXYM1H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Regulatory protein unspecific (RGP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teplizumab DMZ3P6C Type-1 diabetes 5A10 Approved [3]
NI-0401 DMEOLVP Autoimmune diabetes 5A10 Phase 1/2 [4]
MEDI-500 DMT3B4G Bone marrow transplantation QB63.6 Terminated [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Regulatory protein unspecific (RGP) TTBMAOZ NOUNIPROTAC Not Available [2]

References

1 ClinicalTrials.gov (NCT00502294) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis. U.S. National Institutes of Health.
2 Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
3 Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
4 Clinical pipeline report, company report or official report of NovImmune.
5 T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.